胚芽干细胞研究: 现在与未来 Embryonic Stem Cell Research: Present and Future

文信容 汉城大学医学院 教授

Moon Shinyong

Professor, College of Medicine, Seoul National University

Embryonic Stem Cell Research: Present and Future

Therapeutic Cloning: Where we are now?

Shin Yong Moon M.D.


Department of Obstetrics and Gynecology

College of Medicine

Seoul National University



Purpose of Embryonic Stem Cell Research Note: Stem Cell Research




It has been hypothesized by scientists that stem cells may, at some point of future, become the basis for treating disease such as Parkinson's disease, diabetes and heart disease.



公益協會選問營



Embryonic Stem Cell; Legal and Ethical Consideration



Normal Conception and Birth

Embryonic stem cells are found to be more clinically promising than adult stem cell but their research has been hindered by et hical consideration.


For those who believe the human embryo from the one cell stage onwards has absolute moral value, equal to that of a new born baby or an adult, any embryo research is ethically unacceptable.

If ES cells turn out to be the best route to cure a particular disease, then many would argue that it would be morally wrong not to use embryos that would otherwise be discarded.

From IVF to Cloned Human Embryonic Stem Cell




- 1. IVF-ET Program(1985)
- 2. Cryopreservation
- 3. Assisted Hatching
- 4. ICSI
- 5. Preimplantation Genetics
- 6. Embryo-coculturte systems
- 7. Human embryonic stem cell (2001.9~): SNUhES 1,2,3 & 4
- 8. Cloned human embryonic stem cell (2004)













Stem Cell Research Center in Korea



www.stem.or.kr



- •Established: 2002.7
- •Research Fund: 7.5 million US dollars / year
- •Sponsor: Ministry of Science and Technology, Korea
- •Location of Center: Seoul National University Hospital




Human Embryonic Stem Cell Bank (2002)

KSCRC REGISTRED STEM CELL LINES


- → Fully characterized human ES Cell line: 36 lines
- → Fully characterized human EG Cell line: 1 line
- → US NIH registered human ES Cell line : 1 line (Miz-hES1)
- → Cloned human ES Cell line : 1 line + 11 lines












Derivation of human embryonic stem cells depending on quality of blastocyst




The arrows indicate the ICM regions. Scale bar, 100 μ m. Blastocyst quality is one of the most important factors: Implantation and pregnancy

- (A) Good blastocyst, which harbor large and distinct ICM, were processed via the immunosurgical method.
 - (B) Expanded blastocyst with small ICM were processed via the partial embryo culture method.
 - (C) Blastocyst with poorly-defined ICM were processed via the whole embryo culture method.



Mechanical transfer of hESC for maintenance (I)




Scale bar, 500 µm.

- A) At day 6, undifferentiated colonies shown on STO feeder layer.
- B) The feeder layers pushed away from hESC colonies using the dissecting pipette.
- C) Complete separation between feeder layer and hESC colonies.
- D) Dissecting with pipette into small clumps.
- E) Completely dissected clumps.
- F) Transfer to new culture dish using the transfer pipette.



Mechanical transfer of hESC for maintenance(II)



The arrow indicate differentiated hES cell


Mechanical separation and transfer of undifferentiated hESCs from differented cells

- A) Differentiated cells at day 6, indicated by arrow within hESC colony.


 B) The feeder layers pushed away from hESC colonies using the dissecting pipette.
- C) Complete separation between feeder layer and hESC colony.
- D) Separation of undifferentiated cells from differentiated cells using the dissecting pipette.
 - The undifferentiated cells are dissected into small clumps.
- E) The differentiated cells remain, and all of the undifferentiated cells are dissected into small clumps.





Enzymatic transfer for large quantities of cells





- A) Undifferentiated hESC colonies were treated with collagenase.
- B) After 30 minutes of enzyme treatment, the cells began to detach around the edges. At this time point, collagenase was removed and new medium was added.
- C) The colonies lifted off the dish by gently pipetting with a 200-µl micropipette.
- D) Multiple colonies completely detached from dish.
- E) The detached hESC colonies were collected in a 15-ml conical tube, allowed to settle to bottom, and pipetted multiple times to make small clumps.
- F) Small clumps transferred to new culture dish: various sizes.

























BMP2-Induced Differentiation





► Culture Condition suspension 30 days attachment 20 days with 0.6 ng/ml BMP2


- **▶** Beating
- · sensitive to temperature change
- keep beating until now
- 25 / min


Cardiomyocytes derived from hES cell express cardiac specific markers and generate beating cluster.• FGF2 and BMP2 appear to enhance cardiomyocyte differentiation from hES cells.




































Protocols for subculture of hES cells

Subculture in every 7-9 days


- → Trypisn (0.05%) or collagenase IV (200 units/ml or 1 mg/ml) : may induce abnormal karyotype (trisomy 12, 17 or 18)
- → Mechanical dissociation: a glass pipet (our lab) or hooked needle





Embryonic Stem Cells for Cell-therapy

- Establishment of embryonic stem cells
- Differentiation of pluripotent stem cells
- Isolation and Separation of Differentiated cells
- Transplantation of Differentiated Cells
- Functional evaluation of transplanted cells



Safety Consideration in Cell-Based Therapy

- 1. Whether cells can be derived that are histocompatible with every individual?
- 2. Whether transplanted pluripotent stem cells will form tumors or otherwise differentiate improperly or inappropriately after transplantation
- 3. Infectious agents that could be present in embryoderived pluripotent stem cells or acquired by stem cells in feeder-dependent culture containing bovine serur



Conclusion

- •Patient-specific stem cells derived in this study are now expected to provide cells in a disease state that can be used to understand disease progression and assist in drug development.
- •In addition, prior to use in the clinic, biological properties of the patient-specific NT-hESCs must be defined, reliable differentiation procedures must be established, and the cells must be free of contaminating undifferentiated cells and potential pathogens.

